arrow_back Back to App

Tax Exemptions for Non-Profits Making Affordable Drugs and Medical Devices

This law establishes a new tax-exempt status for organizations dedicated to manufacturing and distributing essential drugs and medical devices at affordable prices. The goal is to address shortages and high costs, potentially lowering healthcare expenses for patients and public programs like Medicare. These organizations must also agree to prioritize supplying the national strategic stockpile during emergencies.
Key points
New tax exemptions are created for non-profit entities focused on producing and distributing affordable drugs and medical devices.
The focus is on products that are currently in shortage, excessively expensive, or address unmet public health needs, aiming to reduce patient costs.
Organizations receiving this status must grant the government priority access to at least 25% of their stock for the national strategic stockpile in case of identified need.
Strict rules are implemented to prevent commercial, for-profit pharmaceutical companies from controlling these new tax-exempt organizations.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_3325
Sponsor: Sen. Rosen, Jacky [D-NV]
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expanding Access to Affordable Drugs and Medical Devices Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_3325.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What are the main provisions?

Key points include:

  • New tax exemptions are created for non-profit entities focused on producing and distributing affordable drugs and medical devices.
  • The focus is on products that are currently in shortage, excessively expensive, or address unmet public health needs, aiming to reduce patient costs.
  • Organizations receiving this status must grant the government priority access to at least 25% of their stock for the national strategic stockpile in case of identified need.
  • Strict rules are implemented to prevent commercial, for-profit pharmaceutical companies from controlling these new tax-exempt organizations.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Rosen, Jacky [D-NV].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health Taxes